We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Early this year, Johnson & Johnson prostate cancer blockbuster Zytiga took an unexpected hit when a U.S. court stripped away a key patent, opening the prospect of generic launches later this year—a prospect J&J is working hard to avoid